multiQure stock: Granzer deal supports MQ-201 FDA filing for multiQure stock
Published on 10/24/2026 at 04:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRegulatory path and financial strain
- On October 12, 2026, multiQure agreed with Granzer on support for MQ-201 regulatory work.
- For the half year ended June 30, 2026, net loss reached PLN 150.24 million versus PLN 6.06 million.
- The next scheduled report date is November 16, 2026.
multiQure (ISIN PLPRBLG00010) agreed with Granzer Regulatory Consulting & Services on October 12, 2026, to support discussions with the FDA and prepare an investigational new drug application for MQ-201, according to Investing.com. The agreement covers regulatory strategy, FDA meetings and documentation for manufacturing, preclinical work and the planned clinical study.
FDA preparation gains structure
The work is designed to end with submission of the MQ-201 application for permission to begin a clinical trial. The project targets Huntington's disease through an RNA interference gene therapy, while the company also maintains immuno-oncology programs, according to multiQure.
The regulatory step follows a difficult financial period. For the half year ended June 30, 2026, net loss reached PLN 150.24 million, compared with PLN 6.06 million a year earlier, while basic loss per share was PLN 12.59 versus PLN 1.51. MarketScreener reported both comparisons for the period.
What do the next dates show?
The recent chronology links three milestones. On September 29, 2026, the half-year loss was reported at PLN 150.24 million. On October 5, 2026, a director purchase was disclosed at PLN 100,000, according to MamBiznes. On October 12, 2026, the Granzer agreement added MQ-201 to the FDA preparation timeline.
The next scheduled date is November 16, 2026, for the third-quarter 2026 periodic report, according to the company's investor calendar. The calendar also identifies October 17, 2026, as the beginning of the closed period before that report, as shown by multiQure.
Company profile and listing
multiQure is a biotechnology company listed on the Warsaw Stock Exchange Main Market. Its therapeutic portfolio centers on RNA interference treatment for Huntington's disease and other polyglutamine diseases, with additional immuno-oncology projects, according to Bankier.pl. The company reports 225,749,319 shares in its basic information.
Market context: Market report WIG 20.
